KAYS(KAYS)
KAYS
9/2/26
Kaya (KAYS)
Wednesday
12:13 PM
ThesisThe company's continued operational losses and lack of revenue growth are leading to increased skepticism among investors regarding its turnaround potential.
Revenue Outlook
What Moves the Stock
- 01Regulatory approvals for new drugs
- 02Changes in healthcare policy affecting drug pricing
- 03Market competition from other generic drug manufacturers
- 04Operational restructuring outcomes
- 05Pharmaceutical sales - 100%
- 06Increased focus on cost-effective healthcare solutions
- 07Growing demand for generic drugs amid rising healthcare costs
FY2024 Snapshot
- Revenue
- $7.1K
- Rev. Growth
- -96.4%
- Gross Margin
- -5.1%
- Op. Margin
- -28343%
- Net Margin
- -29170%
- Net Income
- $-2M
- NI Growth
- -229%
- EPS
- $-0.07
- 1Y Return
- -99.6%
KAYS Chart
My Notes
- "Management acknowledged the need for significant operational changes to return to profitability."
- Moat: Kaya's competitive advantage is weak due to its negative margins and operational challenges, making it vulnerable to larger competitors.
- value - Investors may look for turnaround opportunities given the current low valuation metrics.
- Interest rates impact Kaya's financing costs and can affect consumer spending on healthcare products…
- Watch on earnings: Gross margin percentage, Regulatory approval rates for new drugs, Market share in key therapeutic segments.
One Sentence Summary:
Kaya: the story is balanced — regulatory approvals for new drugs.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
